BioSpace News Archive

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe.

DarioHealth Corp. announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.

Non-invasive cardiac assessment company Sensydia announced today that it has completed its 225-subject development study at the University of Pittsburgh Medical Center (UPMC).

Lucius Partners, LLC announced the addition of Centaur Bio, Inc. to the company’s portfolio.

Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028 Report highlights:

Advisors bring large-scale medical research, statistical, epidemiological, operational and funding expertise to the company